These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 6171962)

  • 41. Clinical assessment of dopamine receptor blockade.
    Sedvall G; Bjerkenstedt L; Lindström L; Wode-Helgodt B
    Life Sci; 1978 Aug; 23(5):425-9. PubMed ID: 29184
    [No Abstract]   [Full Text] [Related]  

  • 42. Relations of clinical features, subgroups and medication to serum monoamines in schizophrenia.
    Oades RD; Klimke A; Henning U; Rao ML
    Hum Psychopharmacol; 2002 Jan; 17(1):15-27. PubMed ID: 12404703
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Apomorphine in schizophrenia.
    Hollister LE; Davis KL; Berger PA
    Commun Psychopharmacol; 1980; 4(4):277-81. PubMed ID: 6115735
    [No Abstract]   [Full Text] [Related]  

  • 44. Biochemical studies of children with the syndromes of autism, childhood schizophrenia and related developmental disabilities: a review.
    Ritvo ER
    J Child Psychol Psychiatry; 1977 Sep; 18(4):373-9. PubMed ID: 914908
    [No Abstract]   [Full Text] [Related]  

  • 45. Impact of neuroleptic medications on continuous performance test measures in schizophrenia.
    Epstein JI; Keefe RS; Roitman SL; Harvey PD; Mohs RC
    Biol Psychiatry; 1996 May; 39(10):902-5. PubMed ID: 8860194
    [No Abstract]   [Full Text] [Related]  

  • 46. [Prediction of therapeutic response in depressive states].
    Radat F; Morand P
    Ann Med Psychol (Paris); 1996 May; 154(2):89-102. PubMed ID: 8694405
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cerebrospinal fluid 5-hydroxyindoleacetic acid and homovanillic acid in the pediatric opsoclonus-myoclonus syndrome.
    Pranzatelli MR; Huang Y; Tate E; Stanley M; Noetzel MJ; Gospe SM; Banasiak K
    Ann Neurol; 1995 Feb; 37(2):189-97. PubMed ID: 7531417
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effect of augmentation with moclobemide on symptoms of schizophrenia.
    Silver H; Aharon N; Hausfater N; Jahjah N
    Int Clin Psychopharmacol; 1999 May; 14(3):193-5. PubMed ID: 10435775
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Determination of methylnicotinamide in the blood and urine as a means of controlling neuroleptic treatment effectiveness].
    Mys'ko GN
    Vrach Delo; 1982 Jan; (1):98-9. PubMed ID: 6122307
    [No Abstract]   [Full Text] [Related]  

  • 50. Predicting medication-free treatment response in acute psychosis: cross-validation from the Finnish Need-Adapted Project.
    Bola JR; Lehtinen K; Aaltonen J; Räkköläinen V; Syvälahti E; Lehtinen V
    J Nerv Ment Dis; 2006 Oct; 194(10):732-9. PubMed ID: 17041284
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Heterogeneity of treatment effects in schizophrenia.
    Stroup TS
    Am J Med; 2007 Apr; 120(4 Suppl 1):S26-31. PubMed ID: 17403379
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Atypical antipsychotics and the relevance of glutamate and serotonin.
    van der Heijden FM; Tuinier S; Fekkes D; Sijben AE; Kahn RS; Verhoeven WM
    Eur Neuropsychopharmacol; 2004 May; 14(3):259-65. PubMed ID: 15056486
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of antipsychotic medications on sleep in schizophrenia.
    Krystal AD; Goforth HW; Roth T
    Int Clin Psychopharmacol; 2008 May; 23(3):150-60. PubMed ID: 18408529
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Model-based gene selection shows engrailed 1 is associated with antipsychotic response.
    Webb BT; Sullivan PF; Skelly T; van den Oord EJ
    Pharmacogenet Genomics; 2008 Sep; 18(9):751-9. PubMed ID: 18698228
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ventricular fluid 5-hydroxyindoleacetic acid concentrations during human sleep.
    Wyatt RJ; Neff NH; Vaughan T; Franz J; Ommaya A
    Adv Biochem Psychopharmacol; 1974; 11(0):193-7. PubMed ID: 4367645
    [No Abstract]   [Full Text] [Related]  

  • 56. [Neurophysiological approach to the pathophysiology of the manic-depressive psychosis].
    Okuma T; Ogura C
    Seishin Shinkeigaku Zasshi; 1973 May; 75(5):281-91. PubMed ID: 4593207
    [No Abstract]   [Full Text] [Related]  

  • 57. Recent studies of psychophysiology in schizophrenia.
    Spohn HE; Patterson T
    Schizophr Bull; 1979; 5(4):581-611. PubMed ID: 42141
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Neuroleptics reduce spinal fluid cyclic AMP in schizophrenic patient.
    Biederman J; Rimon R; Ebstein R; Zohar J; Belmaker R
    Neuropsychobiology; 1976; 2(5-6):324-7. PubMed ID: 197445
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Biological markers of depression].
    Ansseau M
    Rev Med Liege; 1986 May; 41(9):349-60. PubMed ID: 2425409
    [No Abstract]   [Full Text] [Related]  

  • 60. Clinical correlates of CSF cyclic nucleotides in schizophrenia.
    Zohar J; Biederman J; Rimon R; Ebstein R; Belmaker RH
    Am J Psychiatry; 1978 Feb; 135(2):253-5. PubMed ID: 203200
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.